News | July 07, 2025
SPARC incorporates subsidiary ‘Genokine Biotech’
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Subscribe To Our Newsletter & Stay Updated
